Market revenue in 2023 | USD 6,392.7 million |
Market revenue in 2030 | USD 8,953.4 million |
Growth rate | 4.9% (CAGR from 2023 to 2030) |
Largest segment | Otc rdt |
Fastest growing segment | OTC RDT |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | OTC RDT, Professional RDT |
Key market players worldwide | ACON Laboratories, Abbott Laboratories, BD, BioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, Cardinal Health Inc, Creative Diagnostics, Roche, McKesson Corp, Meridian Bioscience, Trinity Biotech PLC ADR, Zoetis Inc Class A, Artron Bioresearch, Alfa Medical Group, BioNTech SE ADR, Sight Diagnostics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rapid medical diagnostic kits market will help companies and investors design strategic landscapes.
Otc rdt was the largest segment with a revenue share of 64.04% in 2023. Horizon Databook has segmented the U.S. rapid medical diagnostic kits market based on otc rdt, professional rdt covering the revenue growth of each sub-segment from 2018 to 2030.
The outbreak of novel coronavirus (COVID-19) has created an urgent demand for rapid diagnostic tests in the U.S. According to the data published by Worldometer, as of June 10, 2020, there have been 2,048,518 confirmed cases of COVID-19 in the U.S., which has led to around 114,255 deaths. Rapid testing allows detection of viruses and helps prevent further transmission by isolating the patient.
To meet this growing demand, numerous diagnostics companies are involved in the development of novel COVID-19 rapid diagnostic tests and are striving to gain approval from the FDA to launch these tests in the U.S.
For instance, on May 8, 2020, Quidel Corporation, an American diagnostic healthcare company, received Emergency Use Authorization (EUA) from the FDA for its new Sofia 2 SARS Antigen FIA for rapid diagnosis of COVID-19.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. rapid medical diagnostic kits market , including forecasts for subscribers. This country databook contains high-level insights into U.S. rapid medical diagnostic kits market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account